Hussman Strategic Advisors Inc. Cuts Position in Aurinia Pharmaceuticals Inc $AUPH

Hussman Strategic Advisors Inc. decreased its holdings in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 64.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 126,000 shares of the biotechnology company’s stock after selling 231,000 shares during the quarter. Hussman Strategic Advisors Inc. owned 0.10% of Aurinia Pharmaceuticals worth $1,392,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC increased its position in shares of Aurinia Pharmaceuticals by 27.2% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 13,892 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 2,973 shares in the last quarter. Ritholtz Wealth Management acquired a new stake in Aurinia Pharmaceuticals in the 3rd quarter valued at $934,000. Nordea Investment Management AB grew its stake in Aurinia Pharmaceuticals by 1.2% in the 3rd quarter. Nordea Investment Management AB now owns 359,100 shares of the biotechnology company’s stock valued at $4,026,000 after acquiring an additional 4,100 shares during the period. State of Alaska Department of Revenue purchased a new stake in Aurinia Pharmaceuticals in the 3rd quarter worth $91,000. Finally, CWA Asset Management Group LLC increased its holdings in Aurinia Pharmaceuticals by 15.0% in the 3rd quarter. CWA Asset Management Group LLC now owns 123,552 shares of the biotechnology company’s stock worth $1,365,000 after acquiring an additional 16,154 shares in the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Performance

AUPH opened at $14.57 on Thursday. Aurinia Pharmaceuticals Inc has a twelve month low of $6.55 and a twelve month high of $16.54. The firm has a market capitalization of $1.92 billion, a PE ratio of 26.02 and a beta of 1.46. The company has a current ratio of 5.76, a quick ratio of 5.17 and a debt-to-equity ratio of 0.15. The firm’s 50-day moving average price is $15.55 and its 200 day moving average price is $13.20.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.07. The business had revenue of $73.47 million for the quarter, compared to analyst estimates of $67.70 million. Aurinia Pharmaceuticals had a net margin of 29.28% and a return on equity of 25.19%. As a group, sell-side analysts expect that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Bloom Burton lowered shares of Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, January 21st. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $15.00 price objective (up from $9.00) on shares of Aurinia Pharmaceuticals in a report on Wednesday, November 5th. Leerink Partners cut Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and increased their target price for the company from $15.00 to $16.00 in a report on Wednesday, December 3rd. Finally, Jefferies Financial Group upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the company from $10.00 to $21.00 in a research report on Friday, November 7th. Two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Aurinia Pharmaceuticals has an average rating of “Hold” and an average target price of $17.25.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.